Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

scientific article published on 24 June 2008

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2007-05-092882
P932PMC publication ID2518894
P698PubMed publication ID18577710
P5875ResearchGate publication ID5277938

P50authorNeil E KayQ54295335
John G GribbenQ61132226
William G WierdaQ64026278
Michael J. KeatingQ66429598
John C. ByrdQ66429603
Donna NeubergQ87319577
Michael R GreverQ87630424
Kanti RaiQ90696852
Laura Z RassentiQ114341050
P2093author name stringThomas J Kipps
Feng He
Jennifer R Brown
Andrew W Greaves
Sonia Jain
P2860cites workGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemiaQ24675399
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemiaQ33873337
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.Q33873343
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.Q33956997
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatmentQ34382878
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.Q34521017
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimensQ35954301
CD38 as a prognostic marker in CLL.Q36194534
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemiaQ36285608
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemiaQ36478480
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemiaQ36914070
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st centuryQ40118546
CLL biology and prognosisQ43536921
Clinical significance of CD38 expression in chronic lymphocytic leukemiaQ43775864
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.Q44083652
CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients.Q44170509
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemiaQ44189657
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.Q44605532
ZAP-70 expression and prognosis in chronic lymphocytic leukaemiaQ44730335
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemiaQ44859885
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasmsQ45247281
Regulation of protein tyrosine kinase activation by the T-cell antigen receptor zeta chainQ46103645
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemiaQ46112511
Molecular and genetic insights into T cell antigen receptor signal transductionQ46279345
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia.Q46472325
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemiaQ47869313
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.Q51119490
The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience.Q53661979
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.Q53864608
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.Q55036524
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemiaQ58041773
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factorQ58042045
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemiaQ60358526
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potentialQ61640131
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.Q63347003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileQ73023141
Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemiaQ73152569
When and how to treat chronic lymphocytic leukemiaQ73291688
CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemiaQ73660995
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemiaQ74064365
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemiaQ77637148
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysisQ79569349
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemiaQ80397477
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemiaQ81324241
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemiaQ82286248
The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemiaQ82766574
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectlymphocyteQ715347
leukemiaQ29496
chronic lymphocytic leukemiaQ1088156
P304page(s)1923-1930
P577publication date2008-06-24
P1433published inBloodQ885070
P1476titleRelative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
P478volume112

Reverse relations

cites work (P2860)
Q57279275A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia
Q34917625A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
Q35220403Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia
Q37517160Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia
Q34549313Allogeneic transplantation for chronic lymphocytic leukemia
Q31096565An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Q33965688Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia
Q50569242Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
Q58436696Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia
Q28744086Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells
Q36471596Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia
Q37176527B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome
Q37519737Bendamustine therapy in chronic lymphocytic leukemia
Q33886052Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia
Q36862781Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications
Q37324992Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia
Q35042003CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia
Q44020427CD1d expression as a prognostic marker for chronic lymphocytic leukemia
Q33517828CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: patient survival in comparison to age- and sex-matched population data
Q42770092CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
Q41488705Cellular origin and pathophysiology of chronic lymphocytic leukemia
Q37615541Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
Q87869046Chronic lymphocytic leukaemia
Q37771664Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells
Q57034197Chronic lymphocytic leukemia treatment algorithm 2018
Q36826893Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015
Q26752467Chronic lymphocytic leukemia: a clinical review including Korean cohorts
Q37734199Chronic lymphocytic leukemia: putting new treatment options into perspective
Q33856248Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis
Q36906625Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia
Q47696260Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia
Q64097680Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL
Q39431594Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.
Q50200689Cryptochrome-1 Gene Expression is a Reliable Prognostic Indicator in Egyptian Patients with Chronic Lymphocytic Leukemia: A Cohort Prospective Study
Q35036721Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia
Q34008593Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Q42228343Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran
Q33910990Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia
Q37892409Detection methods of ZAP-70 in chronic lymphocytic leukemia
Q35653850Developing Molecular Signatures for Chronic Lymphocytic Leukemia
Q34418874Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Q92158068Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations
Q34349298Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia
Q46333840Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.
Q33832050ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver
Q64062317Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia
Q36462375Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Q38239271Emerging roles for the FCRL family members in lymphocyte biology and disease
Q92052916Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia
Q36166026Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine
Q50889970External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.
Q37108980Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder
Q38791698First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study.
Q40429099Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia
Q34008866Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
Q37964914Front-line therapy for chronic lymphocytic leukemia
Q36291109Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling
Q33587644Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia
Q38819164Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Q33744997Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go
Q91753087Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
Q36886172High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients.
Q37427988High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia
Q33813862High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival
Q53192790Histone deacetylase in chronic lymphocytic leukemia.
Q34137158How I treat CLL up front
Q37537363How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia
Q35814897IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
Q44563802IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group.
Q38263806Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia
Q37097096Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
Q33634389Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.
Q28533669Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs
Q35188629Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.
Q36124370Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation
Q37579289Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia
Q64960368Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia.
Q42037602Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells
Q38046045Inhibitors of B-cell receptor signaling for patients with B-cell malignancies
Q37412319Karyotype-specific microRNA signature in chronic lymphocytic leukemia
Q35143479LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia
Q33859881Large-scale analysis of DNA methylation in chronic lymphocytic leukemia
Q33796183Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium
Q33774513Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
Q36942667Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia
Q37187536Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
Q45806334Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
Q38755788Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies
Q53108840Monoclonal B-cell lymphocytosis: definitions and natural history.
Q36925185Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
Q33841975Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia
Q35875424ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress
Q88636732Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Q40560266Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial
Q35707206Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia
Q38259446Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.
Q83174110Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia
Q37306304Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia
Q33396594Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia
Q34257190Predicting survival in chronic lymphocytic leukemia
Q37879960Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study
Q91708724Prognosis Factors in Chronic Lymphocytic Leukemia
Q38345576Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma
Q38691341Prognostic Factors for Chronic Lymphocytic Leukemia
Q87856666Prognostic Factors in the Era of Targeted Therapies in CLL
Q34166551Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation
Q37801267Prognostic factors in chronic lymphocytic leukemia-what do we need to know?
Q37738554Prognostic factors in low-grade non-Hodgkin lymphomas
Q33758834Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
Q89637413Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Q51151301Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry.
Q37188389Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia
Q64244355Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia
Q36097697Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia
Q40185340Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.
Q37004820Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia
Q41768675Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers
Q37387647Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
Q41915878Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells
Q89879065Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
Q34348572Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review
Q38189089Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia
Q33822016SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course
Q46467775Selective Anticancer Activity of Acacetin Against Chronic Lymphocytic Leukemia Using Both In Vivo and In Vitro Methods: Key Role of Oxidative Stress and Cancerous Mitochondria
Q37195045Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results
Q36194254Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans
Q54704847Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
Q38062922Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype
Q39085428State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia
Q24642921Stem cell transplantation in chronic lymphocytic leukemia
Q37948956Surface profiles for subclassification of chronic lymphocytic leukemia.
Q87420514TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia
Q49951221Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Q36762433Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.
Q36165173The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
Q37130881The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Q38871618The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia
Q34542102The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Q28278125The molecular pathology of cancer
Q40929264The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity
Q35876861Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.
Q36612587Treatment options for high-risk chronic lymphocytic leukaemia
Q44683894Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia
Q41812846Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia
Q36603887Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia
Q34016413Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
Q34750656White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia
Q36774671Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China

Search more.